Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001040 · ClinicalTrials.gov registry record · Phase 2
Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC
A Phase 2 study of HIV Infections, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 10
- Study locations
NCT00001040 is a Phase 2 study of HIV Infections that has completed, run by Hoffmann-La Roche. The registered enrollment target is 300 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT00001040, a Phase 2 study of HIV Infections, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 10
- Study locations
Study Summary
PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC. SECONDARY: To investigate the pharmacokinetics and effects on various clinical parameters of the three regimens.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Saquinavir
- DRUG Zalcitabine
Study Locations (10)
New York
- Bellevue Hosp / New York Univ Med Ctr - New York
- Univ of Rochester Med Ctr - Rochester
Alabama
- Univ of Alabama at Birmingham - Birmingham
California
- Stanford Univ Med Ctr - Stanford
Colorado
- Univ of Colorado Health Sciences Ctr - Denver
Illinois
- Northwestern Univ Med School - Chicago
Ohio
- Ohio State Univ Hosp - Columbus
Pennsylvania
- Girard Med Ctr - Philadelphia
Texas
- Univ TX Galveston Med Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001040
The ClinicalTrials.gov registry entry for NCT00001040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Zidovudine is the first listed.
NCT00001040 reports 10 study locations spanning 9 distinct geographic areas - top geographies include New York, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00001040 about?
NCT00001040 is a clinical study titled "Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC". PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC. SECONDARY: To investigate the pharmacokinetics and effects on various clinical parame...
What is the current status of trial NCT00001040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants.
What conditions does trial NCT00001040 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00001040?
The interventions under investigation include: Zidovudine (DRUG), Saquinavir (DRUG), Zalcitabine (DRUG).
Who is sponsoring clinical trial NCT00001040?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001040 being conducted?
This trial has 10 study locations across Alabama, California, Colorado, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.